Results 141 to 150 of about 68,288 (264)

BRCA2 [PDF]

, 2017
S. Holdenrieder, P. Stieber
openaire   +1 more source

BRCA2--Branching Out Too? [PDF]

JNCI Journal of the National Cancer Institute, 2015
Margaret R, Spitz, Yanhong, Liu, Christopher I, Amos   +2 more
openaire   +2 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, Volume 20, Issue 3, Page 838-849, March 2026.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients

Сибирский онкологический журнал, 2016
BRCA1 and BRCA2 may contribute in pancreatic cancer (PC) risk, however the selection criteria for BRCA1 testing are poorly defined. The analysis of Russian founder mutation BRCA1 5382insC in 150 PC patients identified 2 carriers.
A. A. Kashintsev, G. A. Yanus, N. Yu. Kokhanenko, V. M. Moiseenko, M. D. Hanevich, L. D. Roman, A. G. Ievleva, A. P. Sokolenko, E. N. Suspitsin, A. I. Budovskiy, A. V. Togo, N. M. Volkov, R. V. Fadeev, M. S. Dinikin, A. K. Ivanova, K. G. Shostko, E. N. Imyanitov   +16 more
doaj  

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, Volume 20, Issue 3, Page 779-803, March 2026.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

NDST3‐Induced Epigenetic Reprogramming Reverses Neurodegeneration in Parkinson's Disease

Advanced Science, Volume 13, Issue 14, 9 March 2026.
NDST3‐mediated epigenetic reprogramming revitalizes neuronal circuits in the substantia nigra and striatum to halt dopaminergic neuron degeneration and restore motor function in Parkinson's disease models. This strategy promotes neuronal maintenance and functional recovery, highlighting NDST3's therapeutic potential in neurodegenerative disorders ...
Yujung Chang, Yongwoo Na, Hyeonjoo Im, Garam Yang, Seungseon Yang, Hyun Soo Shim, Chunggoo Kim, GyeungYun Kim, Hyeok Ju Park, Hee Young Kim, Seung Eun Lee, Wonwoong Lee, Yoon Ha, Sungho Park, Jieun Kim, Won‐Young Cho, Woong Sun, Jong‐Seo Kim, Junsang Yoo   +18 more
wiley   +1 more source

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Nature Cancer, 2020
R. Samstein, C. Krishna, Xiaoxiao Ma, X. Pei, Ken-Wing Lee, V. Makarov, F. Kuo, J. Chung, Raghvendra M Srivastava, T. Purohit, Douglas R. Hoen, Rajarsi Mandal, J. Setton, Wei H. Wu, Rachna Shah, B. Qeriqi, Q. Chang, S. Kendall, L. Braunstein, B. Weigelt, Pedro Blecua Carrillo Albornoz, L. Morris, D. Mandelker, J. Reis-Filho, E. de Stanchina, S. Powell, T. Chan, N. Riaz   +27 more
semanticscholar   +1 more source

Integrative Genomic Profiling of Pediatric Solid Tumors Reveals Clinically Relevant Variants and Chromosomal Arm Aneuploidies Signatures

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Pediatric malignancies have emerged as the leading cause of disease‐related mortality in children, exhibiting distinct etiological and molecular characteristics compared to adult cancers. Despite advances in genomic profiling, the molecular landscape of pediatric solid tumors, particularly in Chinese populations, remains ...
Bingxiao Yan, Jinhu Wang, Jieni Xiong, Shuangai Liu, Yinbing Tang, Ziqi He, Hujin Yan, Bize Guo, Chen Chen, Yijie Zhang, Qinfang Zhu, Jiabin Cai, Min He, Xuan Wu, Junqing Mao, Lifeng Zhang, Weizhong Gu, Zhu Zhu, Zheming Li, Rui Xiao, Qiang Shu, Gang Yu, Ting Tao   +22 more
wiley   +1 more source

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

Nature Medicine, 2017
H. Davies, D. Głodzik, S. Morganella, L. Yates, J. Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, S. Boyault, A. Sieuwerts, P. Simpson, T. King, K. Raine, J. Eyfjord, G. Kong, Å. Borg, E. Birney, H. Stunnenberg, M. J. van de Vijver, A. Børresen-Dale, J. Martens, P. Span, S. Lakhani, A. Vincent‐Salomon, C. Sotiriou, A. Tutt, A. Thompson, S. V. van Laere, A. Richardson, A. Viari, P. Campbell, M. Stratton, S. Nik-Zainal   +32 more
semanticscholar   +1 more source

Male Breast Cancer: Growing Insights and Continuing Challenges

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Breast cancer (BC) in men accounts for less than 1% of all BC diagnoses worldwide. Despite its low incidence, the number of men being diagnosed is increasing. Historically perceived as a predominantly female disease, BC in men has received comparatively limited attention.
Sahar Iftikhar, Elissa Burr, Amal Freigoun, Theo Nearney, Christelle Q. Kanda, Hazel Robinson, Caroline Vermeren, Udana Wickramaratne, Matthew Everest, Luca Foley, Valerie Speirs   +10 more
wiley   +1 more source